Cytosorbents Corporation (CTSO) NASDAQ

0.99

+0.0052(+0.53%)

Updated at October 03 03:09PM

Currency In USD

Cytosorbents Corporation

Address

305 College Road East

Princeton, NJ 08540

United States of America

Phone

732 329 8885

Sector

Healthcare

Industry

Medical - Devices

Employees

149

First IPO Date

August 08, 2006

Key Executives

NameTitlePayYear Born
Dr. Phillip P. Chan M.D., Ph.D.Chief Executive Officer & Director638,1271970
Dr. Robert H. Bartlett M.D.Co-Chairman of Cardiac Surgery Advisory Board & Consultant54,0001939
Ms. Kathleen P. Bloch CPA, M.B.A.Advisor282,7561955
Mr. Peter J. Mariani CPAChief Financial Officer471,7751964
Dr. Efthymios N. Deliargyris FACC, FESC, FSCAI, M.D.Chief Medical Officer538,8211969
Mr. Vincent J. Capponi M.S.President & Chief Operating Officer546,8581958
Jodi HooverExecutive0N/A
Mr. Christopher Cramer M.B.A., M.S.Senior Vice President of Business Development0N/A
Dr. Christian Steiner M.D.Executive Vice President of Sales & Marketing0N/A

Description

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.